S&P 500   4,291.38 (+0.08%)
DOW   33,453.07 (-0.16%)
QQQ   362.42 (+1.16%)
AAPL   174.18 (+1.73%)
MSFT   321.23 (+1.74%)
META   306.65 (+2.15%)
GOOGL   134.16 (+2.52%)
AMZN   130.30 (+2.50%)
TSLA   253.66 (+1.37%)
NVDA   451.15 (+3.72%)
NIO   8.84 (-2.21%)
BABA   86.45 (-0.33%)
AMD   103.20 (+0.37%)
T   14.89 (-0.87%)
F   12.33 (-0.72%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.52 (-0.93%)
DIS   81.37 (+0.39%)
AMC   7.96 (-0.38%)
PFE   33.43 (+0.78%)
PYPL   58.96 (+0.86%)
NFLX   383.48 (+1.56%)
S&P 500   4,291.38 (+0.08%)
DOW   33,453.07 (-0.16%)
QQQ   362.42 (+1.16%)
AAPL   174.18 (+1.73%)
MSFT   321.23 (+1.74%)
META   306.65 (+2.15%)
GOOGL   134.16 (+2.52%)
AMZN   130.30 (+2.50%)
TSLA   253.66 (+1.37%)
NVDA   451.15 (+3.72%)
NIO   8.84 (-2.21%)
BABA   86.45 (-0.33%)
AMD   103.20 (+0.37%)
T   14.89 (-0.87%)
F   12.33 (-0.72%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.52 (-0.93%)
DIS   81.37 (+0.39%)
AMC   7.96 (-0.38%)
PFE   33.43 (+0.78%)
PYPL   58.96 (+0.86%)
NFLX   383.48 (+1.56%)
S&P 500   4,291.38 (+0.08%)
DOW   33,453.07 (-0.16%)
QQQ   362.42 (+1.16%)
AAPL   174.18 (+1.73%)
MSFT   321.23 (+1.74%)
META   306.65 (+2.15%)
GOOGL   134.16 (+2.52%)
AMZN   130.30 (+2.50%)
TSLA   253.66 (+1.37%)
NVDA   451.15 (+3.72%)
NIO   8.84 (-2.21%)
BABA   86.45 (-0.33%)
AMD   103.20 (+0.37%)
T   14.89 (-0.87%)
F   12.33 (-0.72%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.52 (-0.93%)
DIS   81.37 (+0.39%)
AMC   7.96 (-0.38%)
PFE   33.43 (+0.78%)
PYPL   58.96 (+0.86%)
NFLX   383.48 (+1.56%)
S&P 500   4,291.38 (+0.08%)
DOW   33,453.07 (-0.16%)
QQQ   362.42 (+1.16%)
AAPL   174.18 (+1.73%)
MSFT   321.23 (+1.74%)
META   306.65 (+2.15%)
GOOGL   134.16 (+2.52%)
AMZN   130.30 (+2.50%)
TSLA   253.66 (+1.37%)
NVDA   451.15 (+3.72%)
NIO   8.84 (-2.21%)
BABA   86.45 (-0.33%)
AMD   103.20 (+0.37%)
T   14.89 (-0.87%)
F   12.33 (-0.72%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.52 (-0.93%)
DIS   81.37 (+0.39%)
AMC   7.96 (-0.38%)
PFE   33.43 (+0.78%)
PYPL   58.96 (+0.86%)
NFLX   383.48 (+1.56%)

uniQure (QURE) Stock Forecast, Price & News

$6.45
-0.26 (-3.87%)
(As of 11:27 AM ET)
Compare
Today's Range
$6.40
$6.74
50-Day Range
$6.71
$10.62
52-Week Range
$6.40
$28.25
Volume
165,774 shs
Average Volume
789,830 shs
Market Capitalization
$307.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.70

uniQure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
566.2% Upside
$44.70 Price Target
Short Interest
Bearish
8.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of uniQure in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$215,303 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.61) to ($5.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

416th out of 969 stocks

Pharmaceutical Preparations Industry

180th out of 454 stocks


QURE stock logo

About uniQure (NASDAQ:QURE) Stock

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

QURE Price History

QURE Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
uniQure: The AMT-130 Readout
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
5 unique date ideas in NW Arkansas - Axios
Amazon has a unique inflation problem - Reuters
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Company Calendar

Last Earnings
8/01/2023
Today
10/02/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QURE
Employees
501
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.70
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+566.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-126,790,000.00
Net Margins
-166.83%
Pretax Margin
-168.24%

Debt

Sales & Book Value

Annual Sales
$106.48 million
Book Value
$10.17 per share

Miscellaneous

Free Float
45,925,000
Market Cap
$320.07 million
Optionable
Optionable
Beta
1.06
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Matthew Craig KapustaMr. Matthew Craig Kapusta (Age 51)
    CEO & Exec. Director
    Comp: $1.16M
  • Dr. Ricardo Dolmetsch Ph.D. (Age 54)
    Pres & Chief Scientific Officer
    Comp: $911.07k
  • Mr. Christian  KlemtMr. Christian Klemt (Age 50)
    CFO, Principal Financial Officer & GM of Amsterdam Site
    Comp: $566.36k
  • Mr. Pierre Caloz (Age 51)
    Chief Operating Officer
    Comp: $951.1k
  • Prof. Hugo Katus
    Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Jeannette Potts J.D. (Age 61)
    Ph.D., Chief Legal & Compliance Officer
  • Dr. Tamara Tugal Ph.D.
    MBA, Bus. Devel. Director
  • Ms. Erin Boyer
    Chief People & Culture Office
  • Ms. Maria E. Cantor (Age 55)
    Chief Corp. Affairs Officer
  • Mr. Richard Porter Ph.D.
    Chief Bus. Officer













QURE Stock - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price forecast for 2023?

9 equities research analysts have issued 1 year price objectives for uniQure's shares. Their QURE share price forecasts range from $14.00 to $57.00. On average, they expect the company's share price to reach $44.70 in the next year. This suggests a possible upside of 566.2% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2023?

uniQure's stock was trading at $22.67 at the start of the year. Since then, QURE shares have decreased by 70.4% and is now trading at $6.71.
View the best growth stocks for 2023 here
.

Are investors shorting uniQure?

uniQure saw a increase in short interest in September. As of September 15th, there was short interest totaling 3,810,000 shares, an increase of 60.8% from the August 31st total of 2,370,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is currently 3.7 days. Currently, 8.6% of the shares of the stock are sold short.
View uniQure's Short Interest
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.97 by $4.41. The biotechnology company earned $2.42 million during the quarter, compared to the consensus estimate of $168.66 million. uniQure had a negative net margin of 166.83% and a negative trailing twelve-month return on equity of 44.91%.

What ETF holds uniQure's stock ?

Global X Genomics & Biotechnology ETF holds 154,612 shares of QURE stock, representing 1.46% of its portfolio.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $6.71.

How much money does uniQure make?

uniQure (NASDAQ:QURE) has a market capitalization of $320.07 million and generates $106.48 million in revenue each year. The biotechnology company earns $-126,790,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis.

How many employees does uniQure have?

The company employs 501 workers across the globe.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.

This page (NASDAQ:QURE) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -